



(51) International Patent Classification:

C12N 5/16 (2006.01) C12N 15/02 (2006.01)

C12N 7/00 (2006.01) C12N 15/86 (2006.01)

(21) International Application Number:

PCT/US2023/024973

(22) International Filing Date:

09 June 2023 (09.06.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/350,863 09 June 2022 (09.06.2022) US

(71) Applicant: **CHO PLUS INC.** [US/US]; 329 Oyster Pt. Blvd., 3rd Floor, South San Francisco, California 94080 (US).

(72) Inventors; and

(71) Applicants: **FORMAN, Lawrence** [US/US]; c/o CHO Plus Inc., 329 Oyster Pt. Blvd., 3rd Floor, South San Francisco, California 94080 (US). **NGO, Kathy** [US/US]; c/o CHO Plus Inc., 329 Oyster Pt. Blvd., 3rd Floor, South San Francisco, California 94080 (US).


(74) Agent: **SCHIFF, J. Michael** et al.; Kilpatrick Townsend & Stockton LLP, Mailstop: IP Docketing - 22, 1100 Peachtree Street, Suite 2800, Atlanta, Georgia 30309 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: CELL HYBRIDS AS HOST CELLS FOR HIGH EFFICIENCY PRODUCTION OF GENE THERAPY VECTORS AND VIRAL VACCINES

FIG. 1



(57) Abstract: This disclosure provides a technology for adapting host cells to maximize production of viral vectors and particles. Cell hybrids are formed from parental cell lines, and divided or cloned into multiple aliquots for testing. Aliquots are chosen that have high production capacity and phenotypic features for virus production, such as an optimal level of intracellular organelles, and used to establish producer cell lines. The producer cells can be genetically altered to express a transgene that encodes viral elements for production of the viral vectors or particles with a therapeutic payload. The hybrid producer cells generate more viral vectors or particles per cell with higher functional titer, thereby lowering the cost of production of pharmaceutical agents for use in gene therapy and immunization.

Published:

— with international search report (Art. 21(3))